The department of urology at the University of Montreal, chaired by Prof. Saad, for many years  has predominantly been treating prostate cancers and in particular those that evolve in bone metastases. For this reason it has participated in all major trials for the study of drugs for the treatment of metastatic patients, including the latest, based on the administration of Radium 233. According to the outcome of the study, the compound improves survival and reduces bone and spinal complications.